Eructation in the product information
Eructation is the medical term for belching. It appears in two of the three US injection safety tables: the adult pool of three placebo-controlled trials on 2.4 mg lasting up to 68 weeks, and the 68-week trial in adolescents aged 12 and older. [1] The EU product information pools STEP 1–4 and the Canadian monograph STEP 1–3. [2][3]
| Source and population | Placebo | Wegovy® 2.4 mg |
|---|---|---|
| US Table 3: adults (1,261 vs 2,116) [1] | under 1% | 7% |
| US Table 5: adolescents 12 and older (67 vs 133) [1] | 0% | 4% |
| Canadian Table 4: adults, STEP 1–3 [3] | 0.4% | 7.4% |
| EU SmPC 4.8: adults, STEP 1–4 [2] | not given | “common”, mainly during dose escalation |
A small rate with a sharp contrast
Seven per cent is modest next to nausea at 44%. What makes the burping row stand out is the placebo side. For bloating, the placebo group was not far behind (5% versus 7%). For burping, fewer than one in a hundred people on placebo reported it at all, and in the adolescent trial nobody on placebo did. [1] People on placebo followed the same reduced-calorie diet and activity advice as everyone else, so diet change alone does not explain the gap. [1]
A study of the US FDA voluntary reporting database for 2018 to 2022 found 45 digestive signals for semaglutide; eructation had the strongest, meaning it was reported with semaglutide far more often than with other medicines in the database. [4] Disproportionality signals show reporting patterns, not how many users are affected, and cannot prove cause.
What the label leaves out
There is no burping figure for the 7.2 mg dose. Table 4, covering the two 72-week trials, admits only reactions reported in at least 2% of the 7.2 mg arm and more often than in both the 2.4 mg and placebo arms, and eructation is not among them. [1]
Nor does any of the three documents describe what burps smell or taste like. You may read about “sulfur burps” elsewhere; the product information has no such term and no rate for it. [1][2][3] The text of section 6.1 does name hiccups among the digestive reactions that were more frequent on the injection, without a percentage. [1]
Timing, teenagers and neighbouring effects
Section 6.1 says digestive reactions in adults were reported most often during dose escalation, the first 16 weeks in which the weekly injection climbs from 0.25 mg in four-week steps. After two or more missed doses in a row, section 2.4 says escalation should restart at a lower dose to limit digestive reactions, so symptoms tied to escalation may come back after a gap. [1]
In teenagers, the label’s text lists belching with abdominal pain, constipation, reflux, indigestion and gas among reactions more frequent on Wegovy®. [1] In adults, indigestion (9% versus 3%), bloating (7% versus 5%) and reflux disease (5% versus 3%) sat in the same cluster, and the Medication Guide places belching next to heartburn, upset stomach, gas and feeling bloated. [1]
Why burping may happen: three layers
- In the label: semaglutide delays stomach emptying (section 12.2), and digestive reactions concentrate around dose increases. [1] The label does not link either to burping specifically.
- In safety data: the strong reporting signal for eructation fits the trial pattern, and digestive reports for semaglutide tended to start in the first weeks of use. [4] Neither explains the mechanism.
- General background, not shown for Wegovy®: NIH describes belching as gas released from the stomach through the mouth, and explains that some people belch a lot because they swallow air and release it before it reaches the stomach. Chewing gum, sucking hard sweets, fizzy drinks, eating or drinking fast, smoking and loose dentures all add swallowed air. [5]
Steps NIH describes, and other causes
To swallow less air, NIH lists avoiding chewing gum and hard sweets, avoiding fizzy drinks and straws, not talking while eating, eating more slowly and sitting down to eat, getting help to stop smoking, and having dentures checked for fit. [6] It also notes a doctor may suggest smaller, more frequent meals. [6] Novo Nordisk’s patient page suggests asking your healthcare professional about eating more slowly. [8]
Burping can also accompany reflux disease, gastroparesis, functional dyspepsia and other digestive conditions that NIH links with gas symptoms. [5] The Wegovy® label does not suggest any medicine for burping; it asks you to tell your provider about every over-the-counter product you take. [1]
Wegovy® is a registered trademark of Novo Nordisk A/S. PepLabo is not affiliated with or endorsed by Novo Nordisk.
When to get help
The signs and contact information below come from this article’s sourced guidance.